trending Market Intelligence /marketintelligence/en/news-insights/trending/amnwyc2s_sg1yyfcnemfgw2 content esgSubNav
In This List

Moleculin Biotech enters $20M stock purchase deal with PE firm Lincoln Park

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Moleculin Biotech enters $20M stock purchase deal with PE firm Lincoln Park

Moleculin Biotech Inc. agreed to sell up to $20 million of its common shares to private equity firm Lincoln Park Capital LLC.

Chicago-based Lincoln Park Capital, which invests in both public and private companies, will buy the shares at Moleculin Biotech's request over a 36-month period.

Shares sold under the purchase agreement will be limited to 19.99% of the Houston-based cancer drug developer's outstanding common stock.